BrainsWay Reports Record Q4 & Full Year 2025 Financial Results, Projects Strong 27-30% Revenue Growth in 2026

summarizeSummary

BrainsWay reported record Q4 and full year 2025 financial results with substantial revenue and net income growth, alongside strong 2026 guidance and key operational milestones.

check_boxKey Events

• Record Q4 and Full Year 2025 Financial Performance

  Reported Q4 2025 revenue growth of 27% to $14.5 million and full year 2025 revenue growth of 27% to $52.2 million. Net income for the full year increased by 161% to $7.6 million.

• Strong 2026 Financial Guidance Issued

  Projected full year 2026 revenue of $66 million to $68 million, representing 27% to 30% growth, and anticipated Adjusted EBITDA of $12 million to $14 million, an 86% to 100% increase.

• Significant Operational Growth and Regulatory Milestones

  Increased remaining performance obligations by 43% to approximately $70 million and shipped 95 Deep TMS™ systems in Q4 2025, growing the total installed base to around 1,700 systems. The FDA also granted label expansion for Deep TMS for adolescents with MDD and the company secured its first insurer coverage for the accelerated SWIFT™ protocol.

auto_awesomeAnalysis

BrainsWay has delivered a robust earnings report, showcasing significant year-over-year growth in both revenue and profitability for Q4 and the full year 2025. The company's positive 2026 guidance, projecting continued strong revenue and Adjusted EBITDA growth, indicates sustained operational momentum. Key drivers include FDA label expansion for Deep TMS in adolescents and securing the first insurer coverage for its accelerated SWIFT™ protocol, which are expected to fuel further market penetration and revenue generation. This strong performance and optimistic outlook could reinforce investor confidence, especially as the stock trades near its 52-week high.